Brown Advisory
RANI icon

Brown Advisory’s Rani Therapeutics RANI Stock Holding History

Brown Advisory’s Portfolio RANI Stock Details RANI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-32,911
Closed -$16.4K – 1440
2025
Q3 		$16.4K Hold
32,911
– – ﹤0.01% 1376
2025
Q2 		$16.9K Hold
32,911
– – ﹤0.01% 1352
2025
Q1 		$41.5K Hold
32,911
– – ﹤0.01% 1312
2024
Q4 		$45.1K Hold
32,911
– – ﹤0.01% 1327
2024
Q3 		$71.1K Hold
32,911
– – ﹤0.01% 1245
2024
Q2 		$125K Sell
32,911
-1,000
-3% -$5.18K ﹤0.01% 1188
2024
Q1 		$105K Hold
33,911
– – ﹤0.01% 1212
2023
Q4 		$113K Hold
33,911
– – ﹤0.01% 1182
2023
Q3 		$73.8K Hold
33,911
– – ﹤0.01% 1162
2023
Q2 		$140K Hold
33,911
– – ﹤0.01% 1143
2023
Q1 		$175K Hold
33,911
– – ﹤0.01% 1147
2022
Q4 		$200K Buy
+33,911
New +$247K ﹤0.01% 1138

Other funds holding RANI

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
SCP
SymBiosis Capital Partners Bentonville, Arkansas $52.8M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LP
Longaeva Partners Chicago, Illinois $2.7B AUM 37.16% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return

Brown Advisory's RANI Position: Q4 2025 in Review

Brown Advisory sold out of Rani Therapeutics (RANI) in Q4 2025, closing a stake of 32,911 shares — an estimated $16.4K sold.

Brown Advisory first reported a position in RANI in Q4 2022 and held it in 12 quarters. The position peaked at $200K in Q4 2022. 64 funds tracked by Wall St. Rank hold RANI as of Q4 2025.

  • Brown Advisory reported no remaining Rani Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Brown Advisory sold 32,911 Rani Therapeutics shares in Q4 2025, an estimated $16.4K.
  • Brown Advisory first reported a position in Rani Therapeutics in Q4 2022 and held it in 12 quarters.
  • Brown Advisory's Rani Therapeutics position peaked at $200K in Q4 2022.
  • 64 funds tracked by Wall St. Rank held Rani Therapeutics as of Q4 2025.

Based on Brown Advisory's 13F filing for Q4 2025, filed 13 Feb 2026.